Penserra Capital Management LLC Acquires Shares of 22,271 Option Care Health, Inc. (NASDAQ:OPCH)

Penserra Capital Management LLC acquired a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,271 shares of the company's stock, valued at approximately $778,000.

Several other institutional investors and hedge funds have also bought and sold shares of OPCH. Murphy & Mullick Capital Management Corp bought a new position in Option Care Health during the fourth quarter valued at $26,000. Signaturefd LLC grew its holdings in Option Care Health by 487.9% during the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company's stock valued at $28,000 after purchasing an additional 1,005 shares during the period. Quadrant Capital Group LLC grew its holdings in Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock valued at $40,000 after purchasing an additional 1,099 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Option Care Health by 21.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the period. Finally, Johnson Financial Group Inc. bought a new position in Option Care Health during the fourth quarter valued at $47,000. 98.05% of the stock is owned by institutional investors.

Option Care Health Trading Down 0.7%

Shares of OPCH stock opened at $30.64 on Thursday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.54. Option Care Health, Inc. has a 52-week low of $21.39 and a 52-week high of $35.53. The company has a market capitalization of $5.02 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 1.86 and a beta of 0.73. The business's fifty day moving average is $31.90 and its 200 day moving average is $31.26.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the business posted $0.26 earnings per share. The firm's revenue was up 16.3% compared to the same quarter last year. On average, equities research analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OPCH has been the subject of a number of analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $36.00 price target on shares of Option Care Health in a report on Wednesday, June 18th. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 30th. Finally, UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and raised their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Option Care Health presently has an average rating of "Moderate Buy" and a consensus price target of $35.50.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.